Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia
Abstract Background Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, acts as an inhibitor of angiogenesis and is associated with an increased risk of cardiovascular mortality. Administration of stem cells may affect endogenous mechanisms that regulate ADMA produc...
Main Authors: | Juraj Madaric, Martina Valachovicova, Ludovit Paulis, Jana Pribojova, Renata Mateova, Katarina Sebekova, Luba Postulkova, Terezia Madaricova, Maria Bucova, Martin Mistrik, Ivan Vulev |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Stem Cell Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13287-017-0622-2 |
Similar Items
-
Asymmetric Dimethylarginine: Clinical Applications in Pediatric Medicine
by: You-Lin Tain, et al.
Published: (2011-02-01) -
Comparison of two methods for dimethylarginines quantification
by: Vendula Sudová, et al.
Published: (2024-03-01) -
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
by: You‐Lin Tain, et al.
Published: (2017-03-01) -
Symmetrical (SDMA) and asymmetrical dimethylarginine (ADMA) in sepsis: high plasma levels as combined risk markers for sepsis survival
by: Martin Sebastian Winkler, et al.
Published: (2018-09-01) -
Association of dimethylarginines and mediators of inflammation after acute ischemic stroke
by: Chen Shufen, et al.
Published: (2012-11-01)